We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

66 hedge funds and large institutions have $168M invested in Catalyst Pharmaceutical in 2015 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 8

107% more capital invested

Capital invested by funds: $81.3M → $168M (+$87.1M)

58% more call options, than puts

Call options by funds: $128K | Put options by funds: $81K

43% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 14

32% more funds holding

Funds holding: 50 → 66 (+16)

Holders
66
Holders Change
+16
Holders Change %
+32%
% of All Funds
1.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
20
Reduced
14
Closed
8
Calls
$128K
Puts
$81K
Net Calls
+$47K
Net Calls Change
-$46K

Top Buyers

1
CCM
Consonance Capital Management
New York
+$17.5M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$11.1M
3
BC
Broadfin Capital
New York
+$6.07M
4
PA
Perceptive Advisors
New York
+$4.33M
5
BBA
Baker Bros. Advisors
New York
+$3.06M

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$2.9M
2
PCA
Private Capital Advisors
Connecticut
-$2.46M
3
VAM
Visium Asset Management
New York
-$2.21M
4
ACA
Avoro Capital Advisors
New York
-$1.64M
5
GTC
Ghost Tree Capital
New York
-$743K
Name Holding Trade Value Shares
Change 		Change in
Stake
TC
51
TradeLink Capital
Illinois
$75K +$62.1K +17,220 New
RCM
52
Rotella Capital Management
Washington
$73K +$60.7K +16,852 New
HCM
53
Highbridge Capital Management
New York
$64K -$123K -34,035 -70%
EGM
54
Engineers Gate Manager
New York
$64K +$53.6K +14,882 New
BIM
55
BlackRock Investment Management
Delaware
$52K +$7.75K +2,150 +22%
GC
56
Guggenheim Capital
Illinois
$49K +$40.9K +11,355 New
Commonwealth Equity Services
57
Commonwealth Equity Services
Massachusetts
$48K +$39.7K +11,000 New
BA
58
BlackRock Advisors
Delaware
$43K – – –
Creative Planning
59
Creative Planning
Kansas
$36K -$4.04K -1,120 -12%
VIA
60
Vantage Investment Advisors
Pennsylvania
$26K +$10.8K +3,000 +100%
TRCT
61
Tower Research Capital (TRC)
New York
$19K +$15.5K +4,301 New
LTFS
62
Ladenburg Thalmann Financial Services
Florida
$13K +$10.8K +3,000 New
AIM
63
Advantage Investment Management
Iowa
$7K -$1.8K -500 -25%
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
$7K -$1.44K -400 -20%
Bank of Montreal
65
Bank of Montreal
Ontario, Canada
$6K – – –
OM
66
Opaleye Management
Massachusetts
– -$2.9M -975,000 Closed
PCA
67
Private Capital Advisors
Connecticut
– -$2.46M -826,500 Closed
VAM
68
Visium Asset Management
New York
– -$2.21M -742,289 Closed
ACA
69
Avoro Capital Advisors
New York
– -$1.64M -550,670 Closed
GTC
70
Ghost Tree Capital
New York
– -$743K -250,000 Closed
HVC
71
Healthcare Value Capital
New Jersey
– -$149K -50,000 Closed
Simplex Trading
72
Simplex Trading
Illinois
– -$12K -4,087 Closed
Citigroup
73
Citigroup
New York
– +$101 +28 New
1 2
3

CPRX Hedge Fund Activity: Q1 2015 in Review

66 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2015, worth a combined $168M — up 107% from $81.3M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CPRX positions and 8 closed out — a net gain of 16 holders — while 20 added to existing stakes and 14 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $17.5M. The largest seller was Opaleye Management, exiting entirely with an estimated $2.9M sold.

  • 66 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2015, up from 50 in Q4 2014.
  • Funds reported $168M of Catalyst Pharmaceutical stock for Q1 2015, up 107% quarter-over-quarter.
  • 24 funds opened new Catalyst Pharmaceutical positions in Q1 2015 and 8 closed out, a net change of +16 holders.
  • The largest Catalyst Pharmaceutical buyer in Q1 2015 was Consonance Capital Management, an estimated $17.5M added.
  • The largest Catalyst Pharmaceutical seller in Q1 2015 was Opaleye Management, an estimated $2.9M sold.

Based on aggregated 13F filings for Q1 2015.